

Contents

1. Mycobacterium Leprae	1
◆ Lepromin Test 3	
◆ Significance of Lepromin Test 3	
2. Epidemiology of Leprosy	4
◆ Global distribution 4	
◆ Distribution in India 5	
◆ Changing Scenario 5	
◆ Age at Onset 7	
◆ Sex Prevalence 7	
◆ Family Incidence 7	
◆ Individual Factors 8	
3. Pathogenesis, Pathology and Evolution of Classification	9
◆ Indeterminate Leprosy 10	
◆ Lepromatous Leprosy 10	
◆ Borderline Leprosy 13	
4. Immunology of Leprosy	17
◆ Lepromin Test 17	
◆ Epicutaneous Sensitization to Dinitrochlorobenzene (DNCB) 17	
5. Classification of Leprosy	20
◆ Indian Leprologists' Association Classification (1955) 20	
◆ Field Workers' Classification 21	
◆ Ridley and Jopling's Classification (1966) 21	
◆ Tuberculoid Tuberculoid (TT) 21	
◆ Borderline Tuberculoid (BT) 21	
◆ Borderline Borderline (BB) 22	
◆ Borderline Lepromatous (BL) 22	
◆ Lepromatous Lepromatous (LL) 22	
6. Tuberculoid Leprosy	24
◆ Clinical Features 24	
◆ Variants 26	
◆ Diagnosis 27	
◆ Differential Diagnosis 28	
◆ Treatment 31	

7. Maculo-anesthetic Leprosy	32
◆ Clinical Features	32
◆ Treatment	34
8. Lepromatous Leprosy	35
◆ Clinical Features	35
◆ Treatment	42
9. Histoid Leprosy	43
◆ Clinical Features	43
◆ Treatment	46
10. Borderline (Dimorphous) Leprosy	47
◆ Clinical Features	47
◆ Treatment	54
11. Indeterminate Leprosy	55
◆ Clinical Features	55
◆ Treatment	56
12. Polyneuritic Leprosy	58
◆ Clinical Features	58
◆ Treatment	61
13. Leprosy in Children	62
◆ Clinical Features	62
◆ Treatment	64
14. Reactions in Leprosy	66
◆ Mechanism	66
◆ Treatment	71
15. Ocular Leprosy	73
◆ Clinical Features	73
◆ Treatment	77
16. Deformities and Disabilities in Leprosy	78
◆ Grading of Deformities/Disabilities	78
◆ Nerve Supply of the Feet	79
◆ Grading of Hand Deformities	79
◆ Grading of Foot Deformities	81
◆ Grading of Facial Deformities	82
◆ Pathogenesis	83
◆ Primary Deformity	84
◆ Secondary Changes Following Nerve Paralysis	87
◆ Deformity Corrective Measures	89

17. Therapy of Leprosy	91
◆ Dapsone 91	
◆ Clofazimine 92	
◆ Rifampicin 93	
◆ Ethionamide 94	
◆ Chemotherapy of Leprosy 94	
18. Newer Antileprosy Drugs	96
◆ Fluoroquinolones 96	
◆ Minocycline 96	
◆ Macrolides 96	
◆ Phenazine 96	
◆ Rifamycin Derivatives 97	
19. Basic Requirements for Implementation of Multidrug Therapy	98
◆ The MDT Regimen 99	
◆ The Basic Requirement which must be met before Implementing MDT 99	
◆ The Framework for Implementation of MDT 101	
20. Drug-resistance, Persisters and Relapse	102
21. Urban Leprosy	106
◆ Epidemiology 106	
◆ Preventive Measures 106	
22. Prevention and Control of Leprosy	108
◆ Treatment 108	
23. Chemotherapy	111
◆ Official Regimens 111	
◆ New MDT Regimens 112	
◆ Needs for both Flexibility and Reliability of MDT Treatment 113	
◆ Absenteeism and Default 114	
◆ Drug Resistance 115	
◆ Recommendation 116	
24. Epidemiology and Control	118
◆ Impact of MDT on Transmission 119	
25. National Leprosy Eradication Program—Indian Scenario	123
◆ Epidemiological Profile and Leprosy Trends in Registered Cases in India 123	
◆ Modified Leprosy Elimination Campaign (MLEC) Validation 124	
◆ Infrastructure for NLEP 125	
◆ Recommendations for NLEP in the Country 125	
26. Leprosy—The Global Scenario	127
◆ Countries Endemic for Leprosy 127	
◆ Leprosy Trends in India from 1985 130	

27. Leprosy Elimination Campaigns **132**

- ◆ Lessons Learnt 133
- ◆ LECs in Future 133

Appendices

I. Bacteriological Status of Newly Detected Cases	135
II. Classification of Newly Detected Leprosy Cases	136
III. Contact Tracing	137
IV. Classification of Disabilities	138
V. Form for Recording Disabilities from Leprosy	139
VI. Leprosy Vaccines	140
VII. Animal Models for Mycobacterium Leprae	141
VIII. Early Diagnosis: Newer Techniques	143
IX. Standard Protocol	144
X. Vocabulary of Generic and Trade Names of the Drugs and Their Availability	147

<i>Index</i>	<i>149</i>
--------------	------------